MannKind/$MNKD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Ticker

$MNKD
Sector
Primary listing

Employees

405

MannKind Metrics

BasicAdvanced
$1.5B
45.15
$0.11
1.02
-

What the Analysts think about MannKind

Analyst ratings (Buy, Hold, Sell) for MannKind stock.

Bulls say / Bears say

Afrezza inhaled insulin brought in $18.3 million for Q2 2025, a 13% increase year-over-year, fueled by strong demand from end users and stepped-up promotional efforts.
MannKind finished Q2 2025 holding $201.2 million in cash, cash equivalents and investments, giving it a secure financial base to support future commercial and clinical plans.
The company submitted a supplemental BLA for pediatric Afrezza to the FDA in June 2025, with a decision expected by early Q4 2025, positioning MannKind to potentially enter the pediatric diabetes market.
Q2 2025 revenue came in at $76.5 million, falling about $2.3 million short of Wall Street’s expectations and causing shares to drop 12% as investors reacted to the sales miss.
Selling, general and administrative expenses jumped 31% year-over-year to $31.6 million in Q2 2025, putting pressure on margins as the company significantly increased spending behind Afrezza and its commercial footprint.
Collaboration and services revenue dropped 12% to $22.8 million, while V-Go sales fell 8% in Q2 2025, highlighting MannKind’s dependence on key products and its limited diversification.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MannKind Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MannKind Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MNKD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs